Koo ... okay gotcha, roger that on Hepa's exiting licensing arrangement rights.

And I agree, selling off just apabetalone for a sizable number is a great option, unless the opportunity is better for the whole kit-n-kaboodle once BP examines the shelves and data. And I mean, we just don't know how much fire and gas is left in the tank, for those who got it to this point?

Who knows, especially after RVX/BP hopefully proves epigenetics, and gets apabetalone to market commercially ... "Maybe" there is $30b in undeveloped potential molecule sales on the shelves, over the next 10-30 years, but we (RVX) will throw it "ALL IN" for another $2b right now? ... in addition to $4-5b for apabetalone. For example. Idk?! :)